nsclc
- 网络非小细胞肺癌(non-small cell lung cancer)；晚期非小细胞肺癌；治疗非小细胞肺癌
nsclcnsclc
非小细胞肺癌(non-small cell lung cancer)
非小细胞肺癌化疗进展 非小细胞肺癌（ nSCLC）中仅有 15％～20％的早期（Ⅰ、Ⅱ期）病人可经手术治 疗，而占其中 80％ …
晚期非小细胞肺癌
晚期非小细胞肺癌（NSCLC）的维持治疗策略 (点击:43)more... 【MedSci专访OCC2013】魏盟：第六医院心内科… (点击:5)ne…
治疗非小细胞肺癌
化疗是治疗非小细胞肺癌（NSCLC）的重要方法之一，尤其是对于丧失手术时机的晚期或复发NSCLC。随着新的化疗药物和化 …
晚期或转移性非小细胞肺癌
对于晚期或转移性非小细胞肺癌（NSCLC）患者，如何选择一线治疗方案才能确保获得最佳转归？学者们带来的临床研究证据 …
非小细胞性肺癌
为非小细胞性肺癌（NSCLC）的首选肿瘤标志物，通常采用ELISA和IRMA法测定。 Cyfra21-1对于肺部鳞癌的阳性率可达70%…
1
The clinical manifestations and chest imaging of PSC were similar to that of other types of non small cell lung carcinomas (NSCLC).
结果PSC发病部位以右肺上叶多见，临床表现及胸部影像学改变与其他类型肺癌相似。
2
Thoracic radiotherapy has been a key component of local treatment for the patients with non small cell lung cancer(NSCLC).
放疗仍是非小细胞肺癌（NSCLC）重要的局部治疗手段。
3
Due to the lack of the valid diagnosis methods of the early-onset lung cancer, unfortunately most patients were diagnosed at late stage.
不幸的是大多数NSCLC患者确诊时已进入晚期，其原因是临床上缺乏用于早期肺癌筛查的方法。
4
Conclusion: chemotherapy combined with Thymosin on post-operative patients of NSCLC can reduce the side effects of chemotherapy.
结论：在非小细胞肺癌术后患者化疗过程中应用胸腺肽可减轻化疗毒副反应。
5
Palliative surgery should be a part of multidisciplinary therapy for selective patients with advanced NSCLC.
在经过选择的晚期非小细胞肺癌患者，减状性手术应为综合治疗的一部分。
6
It indicates that international pharmaceutical companies can take advantages of the resources available to develop more medicines for NSCLC.
说明国际制药公司充分利用现有资源开发出更多的抗NSCLC药物。
7
The methods used to identify disease distribution are the same for NSCLC and SCLC.
此外，确定癌症的分布的方法同样适用于肺癌。
8
None of the htSNP was associated with NSCLC risk in anyone of two case-control studies.
在两个病例对照组中的任何一个htSNP都与非小细胞肺癌易感性不相关。
9
A total of 2281 patients with NSCLC were screened for EGFR mutations in their tumors and, of this group, 327 had mutations.
对总共2281名NSCLC患者肿瘤组织进行EGFR变异筛查。在这些患者中，327例患者检测到变异。
10
Many studies showed that DNA methylation is specific marker of NSCLC in its diagnosis, staging, treatment and prognosis.
研究显示，DNA甲基化是非小细胞肺癌（NSCLC）诊断、分期及治疗预后特异性较强的标识物。
11
COX multivariate survival analysis: TNM stage, PTEN and Ezrin expression is an independent prognostic risk factors in NSCLC patients (p05).
COX模型多因素生存分析显示：TNM分期、PTEN和Ezrin表达是影响NSCLC患者预后的独立危险因素（p0.05）。
12
This article summarized the latest developments in chemotherapy and molecular targeted therapy of non-small cell lung cancer.
本文就近年来NSCLC化疗及分子靶向治疗等方面的研究进展加以综述。
13
Objective To evaluate the clinical effect and toxicity of pemetrexed in treating elder advanced non. small cell lung cancer(NSCLC).
目的观察培美曲塞联合顺铂治疗老年中晚期非小细胞肺癌（NSCLC）的临床疗效和毒性反应。
14
Objective To investigate the economic effects of three chemotherapy schemes in the treatment of non- small cell lung cancer (NSCLC).
目的探讨晚期非小细胞肺癌（NSCLC）不同化疗方案的临床疗效和经济学效果。
15
What proportion of your NSCLC patients would you conduct this test?
您的NSCLC患者中大概有多少比例的患者会去接受检测？
16
The treatment options and associated mortality for NSCLC change dramatically with each stage.
非小细胞肺癌不同的分期其死亡率以及治疗方法的选择也并不相同。
17
However, little was known about connection between inactivation of the TGFBR1 gene and the presence of CpG methylated promoter in NSCLC.
但是，到目前为止还没有关于TGFBR1基因失活及其启动子区CpG位点的甲基化存在情况与非小细胞肺癌的关系的研究报道。
18
These data demonstrate that H-REV107-1 exerts pro-growth functions within a subset of NSCLC cells in a location-dependent manner.
上述数据显示，H-REV107-1在部分非小细胞肺癌中发挥促生长作用与其分布有关。
19
Methods: Ar-He knife was used combined with chemotherapy of allied two medicines containing Pt to treat NSCLC.
方法：选择直低温介入冷热消融治疗设备（氩氦刀）联合含铂类二药联合化疗方案进行化疗。
20
The main pathology type is small cell lung cancer(SCLC) and non-small cell lung cancer(NSCLC).
病理类型以小细胞肺癌和非小细胞肺癌为主。
21
The results were confirmed using two additional adenocarcinoma NSCLC and two nonadenocarcinoma NSCLC cell lines.
用另外两种NSCLC的腺癌细胞株和两种NSCLC的非腺癌细胞株也证实了这种结果。
22
Conclusion CCR7 could induce lymphangiogenesis and promote lymph node metastasis by up regulating the expression of VEGF-D in NSCLC.
结论CCR7可通过上调VEGF-D表达诱导肺癌组织淋巴管形成、促进淋巴结转移。
23
Objective To observe the toxicity of shenqifuzheng injection combined with NP regimen in the treatment of non-small cell lung cancer(NSCLC).
目的观察参芪扶正注射液配合NP方案化疗治疗非小细胞肺癌（NSCLC）的毒副反应。
24
Objective To observe the difference of sensitiveness of non-small-cell lung cancer(NSCLC) to neoadjuvant chemotherapy(NACT).
目的研究非小细胞肺癌对新辅助化疗敏感度的差异。
25
The incidence of adverse thrombotic events was higher in the advanced NSCLC group than in the non-advanced NSCLC group.
晚期组血栓性不良事件发生率较非晚期组为高。
26
Which statements would you choose to further develop your "story" to encompass the usage of Iressa in 2nd line treatment of advanced NSCLC?
为了更好的发展这个“故事”您会选择哪些描述，且能涵盖把易瑞沙作为晚期NSCLC患者的二线治疗方法？
27
Methods The clinical data of 18 patients with NSCLC and solitary brain metastasis were retrospectively analysed.
方法回顾性分析18例NSCLC单发脑转移患者的临床资料。
28
In retrospect of advances in target therapy of NSCLC, many problems remained to answer.
回顾肺癌靶向治疗的进展，诸多问题需要解决。
29
Afatinib is under development in several solid tumors including non-small cell lung cancer (NSCLC) and head and neck cancer.
Afatinib被开发用于治疗多种实体肿瘤，包括非小细胞肺癌（NSCLC）及头颈癌。
30
Objective: To observe the curative effect and adverse event of non-small cell lung cancer(NSCLC) patients who took ZD1839.
目的：对转移性非小细胞肺癌患者应用ZD1839后的疗效及不良事件进行观察。